184 related articles for article (PubMed ID: 35072287)
1. Exposure-response relationships for the efficacy and safety of filgotinib and its metabolite GS-829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies.
Meng A; Anderson K; Nelson C; Ni L; Chuang SM; Bellanti F; Chang P; Comisar C; Kearney BP; Bartok B; Mathias A
Br J Clin Pharmacol; 2022 Jul; 88(7):3211-3221. PubMed ID: 35072287
[TBL] [Abstract][Full Text] [Related]
2. Filgotinib (GLPG0634/GS-6034), an oral JAK1 selective inhibitor, is effective in combination with methotrexate (MTX) in patients with active rheumatoid arthritis and insufficient response to MTX: results from a randomised, dose-finding study (DARWIN 1).
Westhovens R; Taylor PC; Alten R; Pavlova D; Enríquez-Sosa F; Mazur M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):998-1008. PubMed ID: 27993829
[TBL] [Abstract][Full Text] [Related]
3. Filgotinib (GLPG0634/GS-6034), an oral selective JAK1 inhibitor, is effective as monotherapy in patients with active rheumatoid arthritis: results from a randomised, dose-finding study (DARWIN 2).
Kavanaugh A; Kremer J; Ponce L; Cseuz R; Reshetko OV; Stanislavchuk M; Greenwald M; Van der Aa A; Vanhoutte F; Tasset C; Harrison P
Ann Rheum Dis; 2017 Jun; 76(6):1009-1019. PubMed ID: 27993828
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Mease P; Coates LC; Helliwell PS; Stanislavchuk M; Rychlewska-Hanczewska A; Dudek A; Abi-Saab W; Tasset C; Meuleners L; Harrison P; Besuyen R; Van der Aa A; Mozaffarian N; Greer JM; Kunder R; Van den Bosch F; Gladman DD
Lancet; 2018 Dec; 392(10162):2367-2377. PubMed ID: 30360969
[TBL] [Abstract][Full Text] [Related]
5. Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Genovese MC; Kalunian K; Gottenberg JE; Mozaffarian N; Bartok B; Matzkies F; Gao J; Guo Y; Tasset C; Sundy JS; de Vlam K; Walker D; Takeuchi T
JAMA; 2019 Jul; 322(4):315-325. PubMed ID: 31334793
[TBL] [Abstract][Full Text] [Related]
6. Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Filgotinib, a Selective JAK-1 Inhibitor, After Short-Term Treatment of Rheumatoid Arthritis: Results of Two Randomized Phase IIa Trials.
Vanhoutte F; Mazur M; Voloshyn O; Stanislavchuk M; Van der Aa A; Namour F; Galien R; Meuleners L; van 't Klooster G
Arthritis Rheumatol; 2017 Oct; 69(10):1949-1959. PubMed ID: 28622463
[TBL] [Abstract][Full Text] [Related]
7. Comparative efficacy and safety of 100 mg and 200 mg filgotinib administered to patients with active rheumatoid arthritis: A Bayesian network meta-analysis of randomized controlled trials
.
Song GG; Lee YH
Int J Clin Pharmacol Ther; 2020 Jun; 58(6):293-298. PubMed ID: 32301699
[TBL] [Abstract][Full Text] [Related]
8. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years.
Winthrop KL; Tanaka Y; Takeuchi T; Kivitz A; Matzkies F; Genovese MC; Jiang D; Chen K; Bartok B; Jahreis A; Besuyen R; Burmester GR; Gottenberg JE
Ann Rheum Dis; 2022 Feb; 81(2):184-192. PubMed ID: 34740884
[TBL] [Abstract][Full Text] [Related]
9. Geographic Analysis of the Safety and Efficacy of Filgotinib in Rheumatoid Arthritis.
Combe B; Besuyen R; Gómez-Centeno A; Matsubara T; Sancho Jimenez JJ; Yin Z; Buch MH
Rheumatol Ther; 2023 Feb; 10(1):35-51. PubMed ID: 36205910
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
van der Heijde D; Baraliakos X; Gensler LS; Maksymowych WP; Tseluyko V; Nadashkevich O; Abi-Saab W; Tasset C; Meuleners L; Besuyen R; Hendrikx T; Mozaffarian N; Liu K; Greer JM; Deodhar A; Landewé R
Lancet; 2018 Dec; 392(10162):2378-2387. PubMed ID: 30360970
[TBL] [Abstract][Full Text] [Related]
11. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3).
Atsumi T; Tanaka Y; Matsubara T; Amano K; Ishiguro N; Sugiyama E; Yamaoka K; Westhovens R; Ching DWT; Messina OD; Burmester GR; Bartok B; Pechonkina A; Kondo A; Yin Z; Guo Y; Tasset C; Sundy JS; Takeuchi T
Mod Rheumatol; 2022 Feb; 32(2):273-283. PubMed ID: 34910203
[TBL] [Abstract][Full Text] [Related]
13. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial.
Combe B; Kivitz A; Tanaka Y; van der Heijde D; Simon JA; Baraf HSB; Kumar U; Matzkies F; Bartok B; Ye L; Guo Y; Tasset C; Sundy JS; Jahreis A; Genovese MC; Mozaffarian N; Landewé RBM; Bae SC; Keystone EC; Nash P
Ann Rheum Dis; 2021 Jul; 80(7):848-858. PubMed ID: 33504485
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of filgotinib in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs (DMARDs): A meta-analysis of randomized controlled trials.
Wang Y; Yu L; Ma D; Lu L; Liu B; Liu Z; Ren J; Chu T; Pan L
ARP Rheumatol; 2022 Oct; 1(ARP Rheumatology, nº3 2022):230-243. PubMed ID: 35924369
[TBL] [Abstract][Full Text] [Related]
15. Filgotinib in Rheumatoid Arthritis: A Profile of Its Use.
Kim ES; Keam SJ
Clin Drug Investig; 2021 Aug; 41(8):741-749. PubMed ID: 34304373
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and safety of filgotinib in rheumatoid arthritis patients: data from the GISEA registry.
Fornaro M; Caporali R; Biggioggero M; Bugatti S; De Stefano L; Cauli A; Congia M; Conti F; Chimenti MS; Bazzani C; Perniola S; Atzeni F; Lapadula G; Ferraccioli G; Iannone F;
Clin Exp Rheumatol; 2024 May; 42(5):1043-1050. PubMed ID: 38634362
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
Namour F; Diderichsen PM; Cox E; Vayssière B; Van der Aa A; Tasset C; Van't Klooster G
Clin Pharmacokinet; 2015 Aug; 54(8):859-74. PubMed ID: 25681059
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights.
Raimondo MG; Biggioggero M; Coletto LA; Ramming A; Caporali R; Favalli EG
Expert Rev Clin Pharmacol; 2021 Jun; 14(6):661-670. PubMed ID: 33847204
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the efficacy and safety of tofacitinib and filgotinib in patients with active rheumatoid arthritis: a Bayesian network meta-analysis of randomized controlled trials.
Lee YH; Song GG
Z Rheumatol; 2020 Aug; 79(6):590-603. PubMed ID: 31781849
[TBL] [Abstract][Full Text] [Related]
20. Filgotinib, a novel JAK1-preferential inhibitor for the treatment of rheumatoid arthritis: An overview from clinical trials.
Tanaka Y; Kavanaugh A; Wicklund J; McInnes IB
Mod Rheumatol; 2022 Jan; 32(1):1-11. PubMed ID: 33740386
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]